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Abstract: Phospholipids are important components of the cell membranes of all living 
species.  They  contribute  to  the  physicochemical  properties  of  the  membrane  and  thus 
influence the conformation and function of membrane-bound proteins, such as receptors, 
ion channels, and transporters and also influence cell function by serving as precursors for 
prostaglandins and other signaling molecules and modulating gene expression through the 
transcription activation. The components of the diet are determinant for cell functionality. 
In this review, the effects of macro and micronutrients deficiency on the quality, quantity 
and metabolism of different phospholipids and their distribution in cells of different organs 
is presented. Alterations in the amount of both saturated and polyunsaturated fatty acids, 
vitamins  A,  E  and  folate,  and  other  micronutrients,  such  as  zinc  and  magnesium,  are 
discussed. In all cases we observe alterations in the pattern of phospholipids, the more 
affected  ones  being  phosphatidylcholine,  phosphatidylethanolamine  and  sphingomyelin. 
The deficiency of certain nutrients, such as essential fatty acids, fat-soluble vitamins and 
some metals may contribute to a variety of diseases that can be irreversible even after 
replacement with normal amount of the nutrients. Usually, the sequelae are more important 
when the deficiency is present at an early age. 
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1. Introduction 
The nutritional adequacy of dietary components depends on both their amount and bioavailability in 
the diet. Insufficient dietary intake or excessive loss of macro- and micronutrients strongly affect the 
phospholipids of cellula!r membranes in all living organisms, leading to pathophysiological situations 
of clinical importance in human health.  
The fatty acid composition of membrane phospholipids is likely to be affected by the exogenous 
fatty  acids  from  the diet  or by altered activities  of lipid-metabolizing enzymes such as  fatty  acid 
desaturases [1,2]. Also, some vitamins and trace elements that occur in
 the human diet are known to 
participate in phospholipid homeostasis in different cells. The objective of this review is to provide a 
current overview of the impact of some micronutrient deficiencies of public health significance in 
phospholipid content, distribution and metabolism in different tissues. The effects of the following 
micronutrients: (1) fatty acids; (2) fat-soluble vitamins A and E, with emphasis on their effect on liver, 
which participates in the body-wide distribution of these vitamins, and on the cardiovascular system, 
which is  particularly affected by lipid  peroxidation.  Folate deficiency, the most prevalent vitamin 
deficiency throughout the world, is also discussed. Finally, an overview of (3) dietary zinc (Zn) and 
magnesium  (Mg)  and  their  correlation  with  phospholipid  homeostasis  in  the  lung  and  in  the 
cardiovascular system, respectively, is also given. 
2. Importance of Dietary Fatty Acids on Phospholipid Distribution and Metabolism 
The degree of fatty acid unsaturation in membrane phospholipids determines the biophysical properties 
of  the  membrane,  which  in  turn  influences  many  critical  membrane-associated  functions  [3,4]. 
Depletion of polyunsaturated fatty acids (PUFAs) from membranes might be expected to alter their 
physical and functional properties [5,6]. 
2.1. Phospholipids in Brain 
The  cerebral  cortex  neuronal  membrane  phospholipids  are  composed  of  phosphatidylcholine, 
phosphatidylethanolamine,  phosphatidylserine,  and  phosphatidylinositol  [6].  Phospholipids  contain 
unsaturated fatty acids, in particular docosahexaenoic acid [DHA, 22:6 (n − 3)], the highest levels of 
which are found in the retina and in the cerebral cortex. The degree of unsaturation present in neuronal 
phospholipids fatty acids can mediate the activities of membrane bound enzymes [7].  
The best sources of w-3 DHA in the diet are seafood, algae, and especially coldwater fish and fish 
oil. Alfa-linolenic acid [ALA, 18:3(n − 3)] appears not to be efficient as a good source for DHA, since 
its conversion to eicosapentaenoic acid [EPA, 20:(n − 3)] occurs but is limited in men and the further 
transformation to DHA is very low [8]. 
In  rats,  dietary  deprivation  of  w3  fatty  acids  has  been  associated  with  a  decrease  in  the 
electroretinogram amplitude and impairment in the ability to learn a visual discrimination [9]. In vitro, 
the  growth  of  neurites  increases  the  demand  for  phospholipids,  and  the  biosynthesis  of 
phosphatidylcholine  is  stimulated  in  response  to  nerve  growth  factor  [10].  Infants  fed  with  milk 
artificial formulas exhibit differences in the fatty acid composition of the cortex neuron phospholipids 
as  compared  with  breast-fed  infants.  Artificial  formulas  cause  a  decrease  of  DHA  in Int. J. Mol. Sci. 2011, 12                     
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phosphatidylserine  and  phosphatidylethanolamine,  which  has  been  shown  to  have  clinical 
consequences particularly in preterm infants that present significantly different electroretinographic 
patterns indicating delayed rod photoreceptor maturation compared with those fed with human milk or 
given supplementary DHA [37]. Carlson et al. [12] have shown that DHA supplemented preterm infants 
have  greater  red  blood  cell  phosphatidylethanolamine  DHA  content  and  better  visual  acuity  than 
standard formula fed preterm infants. DHA supplemented infants performed significantly better than 
controls on the Bayley mental scales. It has also been shown that term infants' visual responses at five 
months after birth correlate with erythrocyte DHA concentrations [13].  
Long-term intake of a DHA rich diet is also essential for maintaining and improving the ability of 
learning and memory in elderly humans. Levels of arachidonic [AA, 20:4(n − 6)] and docosatetraenoic 
acids and also DHA decrease considerably in gray matter and hippocampus phospholipids of patients 
with Alzheimer’s disease [14]. Changes in phospholipids metabolite levels have been correlated with 
neuropathological hallmarks of Alzheimer’s disease and cognitive decline. In fact, phospholipids alter 
the production of Aβ40, Aβ42 peptides and consequently Aβ42:40 ratios [15]. 
It is currently known that the fate of DHA in the brain phospholipids is also to generate a protective 
eicosanoid:  neuroprotectin  D1  (NPD1),  which  has  a  potent  anti-inflammatory  and  neuroprotective 
bioactivity. NPD1 reduces Ab42 peptide release from aging human brain cells and is severely depleted 
in Alzheimer’s disease brain [16]. NPD1 also exerts a citoprotective effects on retina [17]. Dietary 
strategies aimed at reducing Aβ levels should take into account interactions of dietary components and 
the metabolic outcomes [15]. 
Using  an  experimental  model  in  rat,  it  has  been  observed  that  percentages  of  both  AA  and 
docosatetraenoic acid of phosphatidylethanolamine and the level AA of phosphatidylcholine in rats fed 
a  sardine  oil  diet  were  lower  than  in  rats  fed  a  palm  oil  diet.  However,  the  level  of  DHA  of 
phosphatidylethanolamine in the sardine oil diet group was higher than that in the palm oil diet group, 
and there were no significant differences in the percentages of stearic, oleic, or palmitoleic acids of 
phospholipids between the experimental diet groups. Adult mice fed a sardine oil diet for a long period 
maintained a higher level of DHA in brain stem phospholipids, higher synaptic membrane fluidity and 
higher maze-learning ability than animals fed a palm oil diet [18]. 
Furthermore, low tissue levels of (n − 3) PUFA in phospholipids, particularly DHA, are implicated 
in postpartum depression. Brain regions of parous female rats fed a diet containing inadequate (n − 3) 
PUFA exhibited a regionally specific decrease of phospholipid DHA content that was not caused by 
either  reproductive  status  or  ALA-deficient  diet  alone,  indicating  that  this  effect  was  due  to  an 
interaction between the diet and the physiological status. Thus, the specific neuronal systems may be 
differentially affected by depletion of brain DHA in the postpartum organism [19]. 
2.2. Phospholipids in Heart 
Several reports indicate that consumption of w-3 fatty acids from fish oil, specifically EPA and 
DHA, decreases the risk of heart failure and attenuates pathologic cardiac remodelling in response to 
pressure overload. However, there are contrasting results in the literature regarding the benefits of 
PUFA  supplementation  for  the  heart.  According  to  a  recent  report  on  the  fatty  acid  content  
of phospholipids of erythrocyte membranes taken from atrial fibrillation patients, DHA in the w-3 Int. J. Mol. Sci. 2011, 12                     
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series was significantly higher in these patients making them more susceptible to oxidative damage 
than controls [20]. 
Dietary  supplementation  with  EPA  +  DHA  may  impact  cardiac  mitochondrial  function  and 
energetics through alteration of membrane phospholipids. EPA+DHA altered fatty acid composition of 
total  mitochondrial  phospholipids  and  cardiolipin  by  reducing  AA  content  and  increasing  DHA 
incorporation [21]. Treatment with w-3 PUFAs DHA and EPA exerts cardioprotective effects, and 
suppresses Ca
2+ induced opening of the mitochondrial permeability transition pore (MPTP). These 
effects are associated with increased levels of DHA and EPA and lower levels of AA [22]. In heart, 
phosphatidylethanolamine highest levels of EPA and DHA were observed following fish oil intake.  
It is known that caloric restriction results in phospholipid depletion, membrane remodelling and 
triacylglycerol  accumulation  in  murine  myocardium.  After  brief  periods  of  fasting  (4  and  12  h), 
substantial decreases occurred in the choline and ethanolamine glycerophospholipid pools in murine 
myocardium.  Remarkably,  the  selective  loss  of  long-chain  polyunsaturated  molecular  species  was 
present  in  the  major  phospholipid  classes  thereby  altering  the  physical  properties  of  myocardial 
membranes [23].  
On the other hand, epidemiological evidence indicates a strong relationship between the intake of 
trans fatty acids, which are formed during the hydrogenation process of cis-unsaturated fats, and the 
risk of coronary heart disease [24,25]. This has been associated to increased LDL cholesterol/HDL 
cholesterol and total cholesterol/HDL-cholesterol ratios, and increased Lp(a) lipoprotein levels when 
trans fatty acids are substituted for saturated fatty acids  [26]. Also, trans fat inhibits the metabolic 
conversion of linoleic acid [18:2(n−6)] to AA and to other n-6 PUFA in aorta, the target tissue of 
atherogenesis [27]. In an atherogenic animal model, Apo E-/-mice fed a low trans fat  from corn oil 
showed an increase of plasma HDL-cholesterol, apo A-I concentrations and the ratio of HDL-cholesterol 
to total cholesterol, while there was a decreases of apo B level compared with hydrogenated trans  
fat [28]. However, further studies are required in order to justify recommendations to use low trans 
fats in food processing. 
2.3. Phospholipids in Bone 
Phospholipids play an important role in the bone marrow as fatty acid reservoirs. It has been shown 
that  fatty  acids  may  influence  bone  metabolism  by  altering  the  biosynthesis  of  prostaglandins.  In 
particular, (n − 3) PUFA increases bone formation by decreasing PGE2 biosynthesis [29]. Changes of 
the membrane phospholipid fatty acid composition may affect bone cell signalling and, potentially, 
bone mineralization. Using the fat-1 mouse, a transgenic model that synthesizes (n − 3) from (n − 6) 
PUFA, it was determined that mice fed with a diet containing 10% safflower oil, phosphatidylcholine 
phosphatidylethanolamine and phosphatidylserine fractions in the vertebrae had a significantly lower 
(n  −  6)/(n  −  3)  ratio  than  wild-type  mice.  In  fat-1  femurs,  these  fractions,  along  with 
phosphatidylinositol, also had a lower (n − 6)/(n − 3) ratio than wild-type mice. DHA was positively 
correlated with bone mineral density in all fractions in the vertebrae, and in phosphatidylinositol and 
phosphatidylserine in the femur [30]. 
An  analysis  of  fatty  acid  composition  of  aspirated  bone  marrow  in  patients  with  hematologic 
diseases has revealed that oleic and palmitic acids concentrations are higher in bone marrow than in 
serum phospholipids. Also, oleic acid but not palmitic acid, increases the rate of alkaline phosphatase Int. J. Mol. Sci. 2011, 12                     
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positive ST2 cells induced by bone morphogenetic protein-2 [31]. It has been proposed that all these 
differences may affect osteoblast differentiation in the bone marrow microenvironment [31]. However, 
the effects of phospholipid fatty acids on osteoblast differentiation are not yet fully understood. 
2.4. Phospholipids in Intestine 
Malnutrition  induced  by  dietary  restriction  in  nursing  piglets  severely  affects  the  intestinal 
histological structure. The amount of DNA and protein, the content of cholesterol, phospholipids and 
triglycerides, and the relative percentages of (n − 6) and (n − 3) long chain-PUFA are lower and those 
of (n − 9) fatty acids are higher in the jejunal and ileal mucosa of protein-malnourished animals. These 
differences, together with those in the distribution of phospholipid species, have been associated with an 
alteration of the activity of membrane-bound hydrolytic enzymes [32]. Long-chain (n − 6) and (n − 3) 
PUFA  in  total  mucosa,  microsomes  and  mucosa  phospholipids  of  jejunum  of  protein-energy 
malnourished  piglets  were  recovered  by  consuming  a  long  chain-PUFA  formula.  Dietary  (n  −  3)  
and (n − 6) long chain-PUFA was efficiently taken up and acylated into membrane phospholipids of  
jejunal cells. These fatty acids in the diet may influence the recovery of intestinal injury caused by 
malnutrition [32]. On the other hand, phospholipids are the main component of the lipoprotein surface, 
and hence a reduction in the content of intestinal phospholipids could lead to alterations of lipoprotein 
conformational structure and secretion [33]. 
Human studies indicate that fatty acid composition of the intestinal mucosa of children with active 
celiac disease show significant differences compared with controls. In celiac children, the level of 
linoleic  acid  is  decreased,  whereas  that  of  its  derivatives  was  elevated,  indicating  increased 
transformation of (n − 6) fatty acid. Furthermore, the level of Mead acid [(20:3(n − 9)] is increased, 
with an increased ratio of Mead acid to AA level, suggesting essential fatty acid deficiency. The fatty 
acid abnormality of intestinal mucosa in these patients was not reflected in serum values [34].  
2.5. Phospholipids in Liver 
High  fat  diet  induces  pronounced  ceramide  and  sphingomyelin  accumulation  in  both  liver  and 
hepatic nuclei and a greater fatty acids saturation status in these sphingolipids [35]. Furthermore, it has 
been observed that liver-specific loss of long chain acyl-CoA synthetase-1 alters phospholipid fatty 
acid  composition.  Small  but  consistent  increases  were  determined  in  the  percentage  of  16:0  in 
phosphatidylcholine  and  phosphatidylethanolamine  and  of  18:1  in  phosphatidylethanolamine  and 
lisophosphatidylcholine,  whereas  concomitant  decrease  were  seen  in  18:0  in  phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylserine and lisophosphatidylcholine [36]. 
It has been shown that low (n − 6)/(n − 3) fatty acid ratio, with fish- or flaxseed oil in a high fat 
diet, improves plasma lipids and beneficially alters the liver fatty acid composition of phospholipids in 
mice. The levels of EPA and DHA in liver phospholipids were significantly increased in both fish and 
flax groups as compared to the control group, with more marked increases in the fish group [37].  
Diet  (n  −  3)  PUFA  content,  and  parity,  affect  liver  and  erythrocyte  phospholipid  fatty  acid 
composition in rats. The effects of sequential pregnancies on the phospholipid fatty acid compositions 
of the maternal liver and erythrocytes have been determined in female rats fed diets containing ALA, 
ALA and preformed DHA (ALA + DHA), or minimal ALA (low ALA). Virgin females, fed the diets Int. J. Mol. Sci. 2011, 12                     
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for commensurate durations, served as a control for reproduction. A significant interaction between 
diet, reproductive status, and duration of treatment was detected only for DHA. Primiparous dams fed 
the ALA and low ALA diet showed a decreased liver DHA content compared with virgin females fed 
the ALA diet. Liver DHA did not decrease further after additional reproductive cycles. Liver DHA 
content was unchanged in porous dams fed the ALA + DHA diet, but virgin females fed this diet 
exhibited a 50% increase in liver DHA after 13 weeks of treatment. Similar changes were observed in 
erythrocytes [38]. Liver phospholipid concentration was 1.27-fold lower with fish protein than with 
casein, respectively. The fish protein diet lowered the AA proportion and the ratio of AA to linoleic 
acid  in  liver  microsomal  phospholipids,  which  was  due  to  the  reduced  microsomal  delta6(w-6) 
desaturation activity [39].  
Using the paradigm of Weindruch et al. [40] different levels of calorie restriction (CR) (125, 85, 50, 
or 40 kcal/week for 1, 3, and 6 months) have been examined in mice. Changes in the fatty acid 
composition of phospholipids from liver, kidneys, heart, brain, and skeletal muscle were observed 
following 1 month of calorie restriction [41].  
2.6. Phospholipids in Serum and Plasma 
Several fatty acids are suitable biomarkers for usual dietary intakes. Serum oleic acid has been 
directly  associated  with  olive  oil,  linoleic  acid  with  sunflower  oil,  pentadecanoic  acid  with  dairy 
products,  (n  −  3)  long  chain-PUFA  with  fatty  fish,  and  trans-monounsaturated  fatty  acids  with 
manufactured foods [42,43]. 
Different pathologies, such as pancreatitis, cancer, diabetes, coronary heart disease, among others, 
can be associated to changes in plasma or serum fatty acids phospholipids. It has been communicated 
that patients  with  alcoholic pancreatitis  showed an increase of monounsaturated  fatty acids  and a 
decrease of AA in plasma phosholipids compared to controls, while no differences were observed in 
values of EPA and DHA or in the ratio of (n − 3) to (n − 6) long chain-PUFA [44].  
Positive associations of serum phospholipids with ALA and negative associations with the ratio of 
linoleic acid to ALA have been related with the risk of prostate and breast cancer [45,46]. 
Furthermore, positive associations with diabetes were observed for stearic acid and total saturated 
fatty acids in plasma phospholipid whereas an inverse association was reported for linoleic acid [63]. 
In  addition,  hydrogenated  trans  fatty  acid  intake  has  been  positively  associated  with  waist 
circumference and glycated hemoglobin [48]. 
The apparently strong findings for an association between plasma or serum phospholipids fatty 
acids  and  different  pathologies  should  be  confirmed  by  nutritional-epidemiologic  studies  in  
different populations. 
3. Vitamin A: Its Effects on Phospholipid Metabolism 
Vitamin A is an essential fat-soluble nutrient for vertebrates. Dietary fat intake is extremely low in 
most  communities  with  vitamin  A  deficiency  [49].  Since  animals  lack  the  capacity  for  de  novo 
synthesis of retinoids, they have an obligatory need to obtain retinoid from the diet as either preformed 
vitamin  A  (all-trans-retinol)  or  provitamin  A  carotenoids.  In  particular,  experimental  evidence Int. J. Mol. Sci. 2011, 12                     
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indicates that phospholipid metabolism is altered in different tissues of the vitamin A-deficient rats, 
which suggests a role for vitamin A in maintaining the integrity of the cell membranes. 
Recently, a beneficial effect on the vitamin A status of rural Bangladesh women and their children 
has  been  shown  when  supplementing  women  with  fat  (20  ml  soybean-oil/day)  from  mid-late 
pregnancy until six months postpartum [49]. 
3.1. Vitamin A Deficiency on Liver Phospholipid Metabolism 
It is well established that liver phospholipid content decreases in rats with vitamin A deficiency [50]. In 
contrast, it increases in guinea pig with the administration of 100,000 U.I. of vitamin A for seven  
days  [51].  The  lower  content  of  total  phospholipid  in  liver  of  vitamin  A-deficient  rats  has  been 
associated to a lower synthesis of phosphatidylcholine and a lower availability of fatty acids [52]. The 
incorporation  of  [
14C]-acetate  into  saponifiable  lipids  and  the  activity  of  acetyl-CoA  carboxylase 
decreases in the hepatic tissue [52]. The low fatty acid synthesis and the depletion of retinoids and 
retinoid X receptors (RXR) found in the vitamin A-deficient liver could explain the low mRNA expression 
of the hepatic transcription factor peroxisome proliferator-activated receptor alpha (PPARalpha) which has 
a pivotal role in the transcriptional regulation of genes involved in cellular lipid metabolism [52].  
Additionally, a significant decrease in total phospholipid content occurs in liver mitochondria of 
vitamin A deficient-rats giving an increased cholesterol/phospholipid relation,  which suggests that 
membrane fluidity can be altered. This, together with the fact that mitochondrial cardiolipin content 
decreases,  could  lead  to  mitochondrial  dysfunction.  Cardiolipin  is  recognized  to  be  an  essential 
phospholipid  in  eukaryotic  energy  metabolism  and  in  maintaining  mitochondrial  structure  and 
function.  A  direct  relationship  between  cardiolipin  loss  and  cytochrome  c  released  from  the 
mitochondria  has  been  identified  as  an  initial  step  in  the  pathway  to  apoptosis  [53].  In  addition, 
deprivation of vitamin A for three months has been shown to induce lipoperoxidation in rat liver [54]. 
Dysfunctional hepatocytes, with a loss in mitochondrial cardiolipin and a decreased mitochondrial 
membrane potential is associated with mitochondrial oxidative stress and pathogenesis and progression 
of different liver diseases [59]. The mitochondrial inner membrane enzyme complexes of the electron 
transport chain also bind phosphatidylcholine and phosphatidylethanolamine, which are required for 
the optimum activity of complexes I and III [60]. 
3.2. Vitamin A Deficiency on Heart Phospholipid Metabolism 
Lipid  metabolism  is  significantly  modified  in  the  heart  of  vitamin  A-deficient  rats.  In  the  left  
ventricle  the  content  of  total  phospholipids  increases  due  to  an  increase  of  phosphatidylcholine, 
phosphatidylethanolamine  and  phosphatidic  acid,  while  cardiolipin,  sphingomyelin,  and 
lisophosphatidylcholine  decrease  compared  to  the  control-fed  group.  Vitamin  A  refeeding  partly 
restores  sphingomyelin  and  lisophosphatidylcholine  contents,  and  completely  restores  cardiolipin, 
phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid proportions to control values [57]. 
Changes in the content of phosphatidylcholine and sphingomyelin in the heart ventricle are explained 
by alterations in their endogenous synthesis. In contrast, it has been shown that the administration of  
33 mg of vitamin A for two days results in a decrease of total phospholipids and phosphatidylcholine 
contents in hearts of rats, due to the impaired synthesis of phospholipids by the diphosphocholine-Int. J. Mol. Sci. 2011, 12                     
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ethanolamine  pathway  [58].  It  is  necessary  to  consider  that  the  maintenance  of  a  constant 
sphingomyelin to cholesterol ratio in membranes is important to support the critical function carried 
out by rafts and related membrane structures [59]. Changes in the contents of lisophosphatidylcholine, 
which is known to stimulate the efflux of 
45Ca
2+ from freshly adult rat cardiomyocytes [60], and 
cardiolipin, which is essential for energy metabolism and in maintaining mitochondrial structure in the 
heart [61], may affect the mitochondrial function.  
Furthermore, vitamin A deficiency induces a decrease of linoleic acid and a high level of saturated 
long-chain fatty acids, 16:0 and 18:0, in the heart mitochondrial phospholipids [57]. Since linoleic acid 
is the main fatty acid of cardiolipins [62], and palmitate has been shown to decrease the content of 
mitochondrial cardiolipin in rat neonatal cardiomyocytes [63], the significant decrease of cardiolipin 
content and the increase of its precursor, phosphatidic acid, in the heart tissue of vitamin A-deficient 
rats [57] could indicate an inhibition of cardiolipin synthesis. In addition, mitochondrial dysfunction 
by cardiolipin oxidative damage has been mainly ascribed to a specific loss in mitochondrial content of 
cardiolipin. It is known that reactive oxygen species (ROS) affect the activity of heart mitochondrial 
complex III leading to mitochondrial dysfunction via cardiolipin oxidative damage [56]. Therefore, 
vitamin A deficiency induces lipid peroxidation in the sera and hearts of rats [64,65]. These findings 
and the fact that oxidized phospholipids formed by lipid peroxidation in membranes are biologically 
active  in  vivo,  inducing  a  pattern  of  inflammatory  genes  in  the  heart  [66],  may  indicate  that  the 
phospholipid increased mass observed in the hearts of vitamin A-deficient rats constitutes a potential 
source of lipid peroxides.  
Vitamin A deficiency also induces a decrease of mitochondrial AA content in the hearts of vitamin 
A-deficient rats. This, and the decrease of its precursor, linoleic acid [57], could be associated with an 
activation of delta-6-desaturase [67]. It has been shown that the mRNA levels of delta-5-desaturase, an 
enzyme that is involved in the desaturation pathway of essential dietary fatty acids for the production 
of PUFA, is more abundant in livers from vitamin A-deficient rats [68]. In addition, the expression of 
delta-5-desaturase is enhanced by PPARalpha [69], whose mRNA expression is increased in the heart 
of vitamin A-deficient rats [57].  
3.3. Vitamin A Deficiency on Aorta Phospholipid Metabolism 
Changes  in  the  level  of  phospholipids  may  compromise  the  integrity  and  function  of  cell 
membranes of the arterial wall. In fact, phospholipid content and synthesis increase in the aorta of rats 
fed a vitamin-A-deficient diet. As it occurs in liver and heart, the increased relative percentage of 
phosphatidylcholine in the aorta of vitamin-A-deficient rats is explained by an increased endogenous 
synthesis of phosphatidylcholine and a high expression of CTP: phosphocholine cytidylyltransferase-
alpha mRNA [70]. Furthermore, it has been demonstrated an increased lipoperoxidation in the aorta of 
vitamin-A-deficient rats [71]. The increased mass of phospholipids would be expected to be a potential 
source of lipid peroxides.  
A vitamin A-deficient diet, in addition to its prooxidative effect, influences cellular and molecular 
regulation of phospholipid metabolism and function, at least, in liver, heart and aorta. Probably, the 
sum of both, vitamin A deficiency and cardiovascular disease, can lead to worse prognosis in patients 
at risk. 
 Int. J. Mol. Sci. 2011, 12                     
 
2416 
4. Vitamin E: Its Effects on Membrane Phospholipids 
Vitamin E is an essential micronutrient for higher mammals and its requirements in humans are 
limited only to alpha-tocopherol because the other forms of vitamin E are poorly recognized by the 
hepatic alpha-tocopherol transfer protein (TTP) and they are not converted to alpha-tocopherol by 
humans [72]. Vitamin E has a major function as a lipid antioxidant to protect polyunsaturated membrane 
lipids against free radical attack [73]. Furthermore, vitamin E has non-antioxidant functions [74]. The 
different behaviors of vitamin E isomers might be related, at least in part, to their specific effects in the 
plasma membrane. 
Alpha-tocopherol  shows  a  propensity  to  associate  with  lipid  rafts.  It  can  act  as  a  membrane 
stabilizer  by  forming  complexes  with  the  products  of  membrane  lipid  hydrolysis,  such  as 
lysophospholipids and free fatty acids, and can directly
 modulate cell signaling, proliferation, and gene 
expression
 [75]. However, the very low levels of alpha-tocopherol reported for whole cell extracts 
question  how  this  molecule  can  successfully  protect  the  comparatively  enormous  quantities  of  
PUFA-containing phospholipids found in membranes that are highly susceptible to oxidative attack. 
Recently, Atkinson et al. [76] have hypothesized that alpha-tocopherol partitions into domains that are 
enriched in polyunsaturated phospholipids, amplifying the concentration of the vitamin in the place 
where it is most needed. These highly disordered domains depleted in cholesterol are analogous, but 
organizationally antithetical, to the well-studied lipid rafts. Thus, the vitamin and PUFA-containing 
phospholipids  would  co-localize  in  non-raft  domains,  which  should  be  translated  into  specific 
biological actions.  
4.1. Vitamin E on Phospholipids in the Cardiovascular System 
It is well known that oxidative stress plays a key role in the pathogenesis of cardiovascular disease. 
A decrease in  nonenzymatic antioxidants  such as  vitamin E and vitamin C has  been observed  in 
patients with acute myocardial infarction in addition to the elevation in ROS production due to the 
ischemic/reperfusion event that occurs in the heart [77]. In the middle cerebral artery (MCA) occlusion 
model of stroke in rats the acute administration of alpha-tocopherol prior to the MCA decreases the 
lipoperoxidation and the volume of infarction, and increases motor performance [78]. 
Although studies performed with cell culture and animal models suggest that alpha-tocopherol has 
promising  antiatherosclerotic  effects  through  its  antioxidant  activity,  the  prevention  of  lipoprotein 
oxidation and the inhibition of platelet aggregation, the results of its supplementation in humans in 
randomized prospective clinical trials have been disappointing [79]. Recent evidence indicates that 
vitamin  E  may  introduce  a  circulatory  risk  by  inducing  flow-disturbing  red  blood  cell  (RBC) 
adherence to blood vessel wall and pro-thrombotic phosphatidylserine exposure. The translocation of 
phosphatidylserine  to  RBC  surface  is  well-known  as  a  potent  mediator  of  RBC/endothelial  cell 
adhesion, facilitating thrombus formation. Koshkaryev et al. [80] found that vitamin E hydrophilic 
analogue-Trolox- does not incorporate into cell membranes, and does not exhibit any of these effects, 
implying that the vitamin E effect is due to its known ability to incorporate into cell membranes. Thus, 
vitamin E elevates RBC/endothelial cell adhesion despite acting as an antioxidant.  Int. J. Mol. Sci. 2011, 12                     
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Currently, the American Heart Association maintains that there are insufficient efficacy data from 
completed  randomized  trials  to  justify  population-wide  recommendations  for  use  of  vitamin  E 
supplements in disease prevention. 
4.2. Vitamin E on Phospholipids of the Liver  
The  liver  is  involved  in  the  body-wide  distribution  of  tocopherol  through  the  hepatic  
alpha-tocopherol  transfer  protein,  which  stimulates  secretion  of  the  tocopherol  from  cultured 
hepatocytes to circulating lipoproteins and facilitates the transfer of tocopherol between membranes 
vesicles in vitro [81]. The alpha-tocopherol function is evident from the observations that mutations in 
the human and mice ttpA gene lead to vitamin E deficiency, accompanied with ataxia and neurological 
disorders [82]. 
The antioxidant properties of vitamin E seem to participate in improving morphological changes 
induced by different agents in the liver. The use of amiodarone, an efficacious antiarrhythmic agent, is 
limited clinically by its cytotoxicity in the form of lysosomal phospholipidosis development and by an 
indirect effect through membrane destabilization. Electron microscopy studies of the liver from rats 
that had received amiodarone and vitamin-E reveals a reduced deposition of phospholipids in  the 
mitochondria [83].  
Although many liver diseases, such as autoimmune liver diseases, viral hepatitis, alcoholic liver 
disease and cirrhosis (any aetiology) have been associated with oxidative stress, meta-analysis studies have 
not found evidence to support or refute antioxidant supplements in patients with liver disease [79,84].  
4.3. Vitamin E on Phospholipids of the Lung  
Alveolar type II cells play a central role in the biosynthesis of surfactant lipids and in the assembly of the 
alveolar surfactant. Lung surfactant consists of 90% phospholipids and 10% proteins. Its main component, 
responsible for its surface tension lowering properties, is dipalmitoylphosphatidylcholine [85]. In addition to 
dipalmitoylphosphatidylcholine, surfactant contains cholesterol and polyunsaturated phospholipids.  
In the lung, polyunsaturated phospholipids species are exposed to strongly oxidizing conditions. 
The  fatty  acids  are  exposed  directly  to  oxidative  air  pollutants  which  are  produced  by  activated 
neutrophils and macrophages [86]. Oxidation leads to degradation of the PUFA and modified proteins. 
This  can  alter  the  surfactant  physicochemical  properties.  By  this  mechanism,  loss  of  surfactant 
function could occur without a decrease in the concentration of dipalmitoylphosphatidylcholine. In 
lungs of cigarette smoking rats the vitamin E level is increased, rather than decreased. This suggests 
that vitamin E may be mobilized from other organs to the lung under oxidative stress, presumably to 
maintain a constant antioxidant level [87]. Antioxidant deficiency may lead to surfactant dysfunction 
and respiratory insufficiency [88]. Vitamin E in the lung can also exhibit non-antioxidant effects that 
are at least in part mediated by the modulation of the activity of protein kinase C [89].  
4.4. Other Vitamin E Actions on Phospholipids 
Most cytotoxic therapies used for cancer treatment, predominantly act by triggering apoptosis in 
target cells. The anticancer activity of vitamin E appears to be caused by several mechanisms, such as 
apoptosis and antiangiogenesis. It is known that ceramide-enriched lipid microdomains can be formed Int. J. Mol. Sci. 2011, 12                     
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by increased amounts of ceramide in cell surface membranes which is regulated by sphingomyelinase 
hydrolysis of raft-associated sphingomyelin to ceramide [90]. The treatment of human MDA-MB-231 
breast cancer cells with alpha-tocopherol ether-linked acetic acid (alpha-TEA), an analogue of vitamin 
E (RRR-alpha-tocopherol) that exhibits anticancer actions in vitro and in vivo in different cancer types, 
induces an increase of the acid sphingomyelinase activity and sphingomyelinase translocation from 
cytosol to the cell surface membrane. This leads to co-localization with the signalling mediators Fas, 
DR5, and FADD, followed by activation of caspases-8 and -9 and apoptosis [91]. Sphingomyelinase 
activation and membrane ceramide accumulation are early events that contribute to α-TEA-induced 
apoptosis in vitro and perhaps in vivo [91]. 
On  the  other  hand,  in  vitro  and  in  vivo  experimental  evidence  indicates  that  tocotrienol,  an 
unsaturated version of vitamin E, exhibits anti-angiogenic properties that may assist in tumor regression. 
The antiangiogenic effects of tocotrienol might be associated with changes in phosphatidylinositol-3 
kinase (PI3K)/PDK/Akt signaling and apoptosis induction in endothelial cells [92].  
Although the above experimental evidences show that non-antioxidant effects of vitamin E and 
analogs are associated to phospholipids metabolism, further experimental and clinical investigation of 
the molecular events induced by vitamin E on phospholipid metabolism and signaling are required to 
confirm a beneficial effect of prolonged administration of high-dose natural vitamin E in reducing 
cancer risk or on the progression of this disease.  
5. Folates: Its Effects on Phospholipid Metabolism  
Folates are members of the B-complex vitamins, which are required for the one-carbon transfer 
reactions  necessary for  DNA synthesis  and biological  methylation  of  a wide variety of essential 
biological substances, including phospholipids, proteins, DNA, and neurotransmitters, thus regulating 
their function [93]. As mammals are unable to synthesize folate de novo, the requirements must be 
satisfied from nutritional sources. Folates are hydrophilic anionic molecules that can only minimally 
traverse biological membranes by simple diffusion, so there exists a well-developed folate membrane 
transport system for the absorption of folate in the intestine [94] and for its uptake in the different 
tissues. Any impairment in these folate transport systems or folate metabolism might lead to a state  
of  folate  deficiency  [95].  Recent  evidence  suggests  that  acute  folate  over  supplementation  results  
in  a  significant  decrease  in  intestinal  folate  uptake  by  down-regulating  the  expressions  of  folate  
carrier (RFC) and proton-coupled folate transporter (PCFT) [96].  
The  folate  pathway  is  closely  linked  to  the  formation  of  homocysteine  and  metabolism  of 
methionine and S-adenosylmethionine (SAM), two compounds that play a central role in biologically 
important  methylation  reactions.  SAM  is  the  methyl  donor  for  >100  different  transmethylation 
reactions [97]. The most studied in the area of lipid methylation are the three successive methylation 
steps  of  phosphatidylethanolamine  resulting  in  the  formation  of  phosphatidylcholine,  which  is  
known  to  increase  membrane  fluidity.  Methylation  reactions  are  required  for  the  synthesis  of 
membrane phospholipids, myelin basic protein and neurotransmitters, three important pathways in  
the  central  nervous  system.  It  has  been  reported  that  individuals  who  are  severely  deficient  in  
5,10-methylenetetrahydrofolate reductase (MTHFR) activity have excessive amounts of homocysteine 
in the blood, developmental delay and vascular diseases [98]. Older heterozygous and homozygous 
knockout mice have abnormal lipid deposition in the proximal portion of the aorta that is consistent Int. J. Mol. Sci. 2011, 12                     
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with the proposed role of MTHFR deficiency in vascular disease [99]. Modification of sarcolemmal 
phosphatidylethanolamine N-methylation has been observed during heart hypertrophy [100].  
Folate intake/status may also influence choline metabolism/status. Choline is a fundamental nutrient 
for the normal function of all cells. In addition to being the precursor for acetylcholine synthesis, it is a 
major methyl group donor [101]. It is required in the synthesis of phospholipids phosphatidylcholine, 
lisophosphatidylcholine, choline plasmalogen, and sphingomyelin [102,103]. In humans, it has been 
shown that (1) choline is used as a methyl donor when folate intake is low; (2) the de novo synthesis of 
phosphatidylcholine, is insufficient to maintain choline status when intakes of folate and choline are 
low, and (3) dietary choline is required by adults in an amount >250 mg/day to maintain plasma 
choline and phosphatidylcholine, when folate intake is low [104]. These results confirm some aspects 
of the metabolic interdependence of folate and choline previously demonstrated in rats. 
In pre-menopausal women, plasma phosphatidylcholine, declined in response to folate restriction 
and increased after folate treatment [105]. Notably, these changes occurred under conditions of steady 
choline intake (349 mg/d) and were probably due to  changes  in  the availability of folate derived  
one-carbon units required for the biosynthesis of phosphatidylcholine, through the PEMT pathway. 
Pemt(-/-) mice fed a choline-deficient diet develop rapid steatohepatitis leading to liver failure. It has 
been demonstrated that liver failure in choline-deficient Pemt(-/-) mice is due to loss of membrane 
integrity caused by a decreased phosphatidylcholine/phosphatidylethanolamine ratio. In addition to 
folate intake, MTHFR C677T genotype is a strong genetic modifier of folate and homocysteine status 
and may influence choline status [105,106]. 
Studies in rodents suggest that dietary intake of choline early in life can diminish the severity of 
memory  deficits  in  aged  animals.  Supplemental  choline  during  pregnancy  results  in  life-long 
enhancement  of  hippocampal  function  in  offspring  [107]  and  the  rate  of  apoptosis  in  fetal 
hippocampus is inversely related to the dietary choline intake of the rat dam [108]. The induction of 
apoptosis is caused by a decrease in membrane phosphatidylcholine concentration [109] because this 
choline ester is needed for normal progression through the cell cycle [110]. Choline insufficiency is 
considered  to  be  rare  in  humans  and  is  manifested  only  during  pregnancy,  lactation,  or 
starvation/fasting, because normal diets contain sufficient choline [111,112]. 
On the other hand, chronic ethanol consumption coupled with folate deficiency leads to rapid liver 
fat accumulation and progression to alcoholic steatohepatitis. An in vivo examination of liver lipid 
metabolism  confirms  that  both  increased  de  novo  lipogenesis  (e.g.,  lipid  synthesis)  and  altered 
phospholipid metabolism (e.g., lipid export) contribute to the excessive accumulation of lipids in liver 
affected by steatohepatitis. In fact, increased liver triglyceride content in micropigs fed a 40% ethanol 
folate-deficient diet without SAM supplementation was accompanied by increased flux through the 
stearoyl-CoA  desaturase  pathway  as  indicated  by  increases  in  the  ratios  of  [16:1(n7)]  to  16:0  
and [18:1(n9)] to 18:0 and suppressed  flux through the fatty acid elongation and PEMT pathways 
compared with controls. SAM supplementation attenuated the triglyceride accumulation associated 
with alcohol [113]. Importantly, MTHFR polymorphism and ethanol intake have been associated with 
colorectal cancers [114].  
Most of the effects of folic acid deficiency are associated to alterations in phospholipid metabolism. 
Since the introduction of folic acid food fortification throughout the world, the prevalence of folic acid Int. J. Mol. Sci. 2011, 12                     
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deficiency has decreased. However, people with excessive alcohol intake and malnutrition are still at 
high risk of this deficiency. 
6. Zinc on Phospholipid Metabolism 
Zinc is an essential dietary  trace element  that has  attained prominence  in  human nutrition and 
health. Zinc deficiency is common in infants and young children in developing countries and leads to 
stunted  growth,  increased  risk  of  infection,  and  possibly  poor  neurodevelopment  [115].  Zinc  is  a 
constituent of hundreds of proteins with catalytic and structural roles and is involved in intermediate 
metabolism,  hormone  secretion  pathways,  and  immune  defense  [116,117].  It  is  also  an  essential 
component  of  many  transcription  factors,  suggesting  that  alterations  in  Zn  status  are  immediately 
translated into changes in gene expression [118,119]. Because Zn-deficiency symptoms very much 
resemble those of essential fatty acid deficiency, a close link between fatty acid metabolism and Zn 
status has been proposed [120,121]. 
6.1. Zn Deficiency on Phospholipids of the Lung  
Reports on the effects of Zn deficiency on lipid metabolism in the respiratory system are relatively 
few. This metal ion has a number of properties which potentially enable it to modulate the function not 
only of airway epithelium, but also of the cells that interact with this tissue. The major phospholipid 
component (at the air-liquid interface) is phosphatidylcholine (70–80%) and numerous reports indicate that 
changes in phosphatidylcholine metabolism are a common feature of the pathophysiology of experimental 
chronic lung injury or adult respiratory distress syndrome. A moderate Zn deficiency (in vivo) can 
induce  a  physiological  stimulus  that  enhances  phospholipid  synthesis  and  changes  especially  the 
pattern of phospholipids in adult rat lung [122,123]. 
The amount of 1-acyl-sn-glycerol-3-phosphate and the diacylglycerol acyltransferase expression 
decreases  significantly in Zn-deficient lung,  while  phosphatidylcholine  increases.  To date, little is 
known about the mechanism of potential coregulation of triglyceride and phospholipid metabolisms. 
Caviglia et  al.  [124]  provided evidence that triglyceride synthetic  enzymes such as  mitochondrial 
glycerol-3-phosphate acyltransferase may indirectly regulate phospholipids synthesis by controlling 
the availability of mainly fatty acids and diacylglycerol for phospholipids formation.  
Also, Zn deficiency is accompanied by an important oxidative and nitrosative stress associated with 
significant  morphological  changes  in  lung  parenchyma  [125,126].  In  addition,  Frey  et  al.  [127] 
demonstrated that fragmented phospholipids increase in the lung of patients with adult respiratory 
distress syndrome [127]. Measurement of antioxidants and the concentration of PUFAs in relation to 
phospholipid- and protein-oxidation products of lung surfactant should be useful as early parameters of 
surfactant dysfunction. 
6.2. Other Effects of Zn on Phospholipids 
Considerable evidence suggests a linkage between dietary deficiency
 of Zn and diverse alterations 
in the absorption of vitamins in the intestinal lumen. The nutritional status of Zn influences the plasma 
and tissue levels of vitamins A and E in animals and humans [128]. Intestinal absorption of fat, retinol, 
and alpha tocopherol has been shown to be impaired in rats fed a low-Zn diet. Under the conditions of Int. J. Mol. Sci. 2011, 12                     
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matched food intakes and body weights between rats fed a Zn-deficient diet and those fed an adequate 
Zn diet, the intestinal absorption of vitamin A was lowered significantly in Zn-deficient rats [129]. The 
lower vitamin absorption levels in Zn-deficient rats occurred in parallel with a significant decrease in 
14C-oleic acid absorption. Noh et al. [130] showed that the luminal hydrolysis of phosphatidylcholine 
to lisophosphatidylcholine by phospholipase A2 may be impaired in  Zn-deficient rats, resulting in 
impaired intestinal absorption of fat and fat-soluble vitamins. A possible defect in phospholipase A2 
produced by Zn deficiency may limit the availability of lisophosphatidylcholine, which in turn slows 
the rate of intestinal chylomicron formation and absorptions of lipids and lipid-soluble vitamins.  
It has been observed in liver of Zn-depleted rats that content of triacylglycerol and proportions of 
cis-9-oleic, cis-11-vaccenic, caprylic, myristic, alpha-linolenic, and eicosapentaenoic acids increases, 
while stearic and arachidonic acids decrease. Also, Zn deficiency reduced fatty acid oxidation. These 
changes produce modification in the composition of phospholipids [131]. Alterations in the expression 
of gene groups functionally linked to hepatic lipogenesis and lipolysis are involved in the above lipid 
modifications.  An  unbalanced  gene  transcription  control  via  PPARalpha  and  SREBP-dependent 
pathways could explain most of the apparently pleiotropic effects of Zn deficiency on fat metabolism, 
especially in the liver [131]. 
Merrells et al. [132] investigated the effect of dietary Zn deficiency on male reproductive system. 
Growing  rats  with  severe  Zn  deficiency  had  a  lower  testis,  seminal  vesicles  and  prostate  
weights,  and  abnormal  sperm  morphology  than  control  rats.  The  dominant  fatty  acid  in  testes  of  
Zn-deficient  rats  was  docosapentaenoic  acid,  comprising  15  and  24%  of  phosphatidylcholine  and 
lisophosphatidylethanolamine,  respectively.  Thus,  severe  Zn  deficiency  during  sexual  maturation 
adversely  affects  sperm  integrity  and  alters  phospholipid  fatty  acid  composition  in  testis  by 
interrupting  essential  fatty  acid  metabolism.  It  has  been  suggested  that  Zn  deﬁciency-associated 
abnormal  testicular  function  is  perhaps  preceded  by  alterations  in  phospholipid  fatty  acid  
composition [132].  
Furthermore, Zn has been implicated in altered adipose metabolism, insulin resistance and obesity. 
Tallman et al. [133] studied the effects of dietary Zn deficiency and supplementation on adiposity, 
serum leptin and fatty acid composition of adipose triglycerides and phospholipids in C57BL/6J mice 
fed low-fat or high-fat diets for a 16 week period. Dietary fat, but not dietary Zn, altered the fatty  
acid  composition  of  adipose  tissue  phospholipid  and  triglyceride  despite  differences  in  Zn  status.  
The high fat-fed mice had reduced adipose Zn concentrations, higher percentage of AA, elevated ratio 
of (n−6)/(n−3), lower ratio of PUFA/SAT and reduced percentage of total (n−3) fatty acids in adipose 
phospholipids,  a fatty  acid  profile associated with obesity-induced risks  for insulin  resistance  and 
impaired glucose transport. Furthermore, serum leptin concentration was positively correlated with 
body weight and body fat, and negatively correlated with adipose Zn concentration. These results 
support an interrelationship among obesity, leptin and Zn metabolism [133].  
7. Magnesium on Phospholipids Metabolism 
7.1. Magnesium on Phospholipids of the Cardiovascular System 
There exists a considerable amount of experimental, epidemiological  and clinical evidence that 
suggests a linkage between Mg dietary deficiency
 and diverse types of cardiovascular alterations. A Int. J. Mol. Sci. 2011, 12                     
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low Mg content in drinking water found in areas of soft water
 and Mg-poor soil is associated with high 
incidence  of  ischemic
  heart  disease,  coronary  vasospasm,  and  sudden  cardiac  death
  [134,135]. At 
present, the average
 dietary intake of Mg has declined from about 450–485 mg/day
 in 1900 to about 
185–235 mg/day for large segments of
 the North American population [136].  
Dietary  Mg  deficiency  results  in  falls  in  myocardial  glycogen,  glucose-6-phosphate,  glycerol 
phosphate, as well as the contents of phosphatidylcholine, phosphatidylethanolamine, diphosphatidyl 
glycerol,  phosphatidylinositol  and  total  phospholipid  phosphorus.  The  mitochondrial  oxidation  of  
long-chain fatty acids is also altered after Mg depletion. These observations are consistent with the 
tenet that prolonged low [Mg
2+] zero can result in marked reduction in oxygen and substrate delivery 
to the cardiac myocytes, with concomitant changes in membrane phospholipids [137].  
Furthermore, a short-term Mg dietary deficiency (21 days) in rat results in an upregulation of the 
two  major  subunits  of  serine  palmitoyl-CoA-transferase,  serine  palmitoyl  transferase  (SPT  1)  
and  SPT  2  (the  rate-limiting  enzymes  responsible  for  the  de  novo  biosynthesis  of  ceramides), 
concomitant with a highly significant release of mitochondrial cytochrome c in left ventricular, right 
ventricular, atrial, and abdominal aortic smooth muscle [138]. This nutritional deficiency can cause a 
biosynthesis of ceramides via two pathways in cardiovascular tissues, viz., via the activation of serine 
palmitoyl-CoA-transferase and sphingomyelinase, which leads to apoptotic events via intrinsic and 
extrinsic  pathways  [138].  The  dietary  Mg  deficiency-induced  membrane  oxidation  leads  to
  the 
generation of ceramides (via the activation of sphingomyelinase) and
 diminished phosphatidylcholine 
synthesis, which act in concert to help induce
 programmed cell death in ventricular, atrial, and vascular 
smooth
 muscle cells in the intact animal [139]. It has been proposed
 that Mg deficiency should be 
added  to  well-known  extracellular
  stimuli  such  as  vitamin  D,  TNF-alpha,  FasL,  IL-1β,  
gamma-radiation,
 UV radiation chemotherapeutic agents, oxidative stress, and
 others, which cause the 
activation of sphingomyelinase and hence of the sphingomyelin-ceramide
 pathway [140]. 
Mg  deficiency  as  a  risk  factor  for  cardiovascular  diseases  has  been  related  to  imbalance  of 
thromboxane and prostacyclin in the vasculature. Low level of Mg in the culture medium of human 
umbilical vein endothelial cells induces a time- and dose-dependent increase in AA release from the cell 
phospholipids,  stimulates 
45Ca
2+  influx,  resulting  in  an  activation  of  phospholipase  A2  (PLA2), 
stimulates  ciclooxygenase-2  (COX-2)  activity  and  enhances  6-keto-prostaglandin  F1alpha 
(PGF1alpha) production [190]. The increased prostacyclin production could provide protection against the 
cardiovascular effect of thromboxane which is increased by Mg deficiency [141].
 
These results extend previous findings that low levels of Mg
2+ in primary
 cultured peripheral and 
cerebral vascular smooth muscle cells
 result in lowered intracellular levels of both phosphatidylcholine 
and sphingomyelin-the
 lower the external level of Mg
2+, the lower were the concentrations
 of both 
phosphatidylcholine and sphingomyelin [139].  
7.2. Magnesium on Phospholipids of the Blood Components 
It has been reported that weanling rats pair-fed with Mg-deficient diets for eight days exhibited an 
increase  in  fluidity  of  erythrocyte
  membranes,  where  a  reduced  ratio  of  sphingomyelin  to 
phosphatidylcholine  and  a  reduced  ratio
  of  cholesterol  to  phospholipid,  but  no  change  in 
phosphatidylcholine content,
  was found [142]. Altura et al. [140] have shown that
 short-term dietary Int. J. Mol. Sci. 2011, 12                     
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deficiency  of  Mg  in  an  adult  rat  results
  in  decreased  serum  levels  of  both  phosphatidylcholine  
and sphingomyelin.  
Sphingomyelin  and  phosphatidylcholine  are  the  major  phospholipids
  in  very  low-density 
lipoproteins,  and  serum  lipids  of  Mg-deficient  rats  and  rabbits
  exhibit  dramatic  changes  in  these 
lipoproteins and significant elevations in serum/plasma triglycerides [143] along with increases in 
phospholipids  [144].  It  is  possible
  that  significant  changes  in  sphingomyelin/phosphatidylcholine 
containing lipoproteins,
 and the current report of lowered serum sphingomyelin and phosphatidylcholine 
concomitant
 with lipid peroxidation, could be in part due to a
 redistribution of SM and phosphatidylcholine 
in the changing lipoprotein fractions
 independent of sphingomyelinase activity [140]. 
Mg
2+ has been reported to increase the affinity between coagulation factors IXa and VIIIa [145] 
and, remarkably, it does not enhance the rate of factor X activation by IXa/VIIIa unless phospholipids 
are included in the system [145]. Recent evidence indicates that Mg
2+ binding to the specific sites in 
the C-terminal half of the IX/IXa γ-carboxyglutamic acid (Gla) domain prepares it for Ca
2+ binding to 
the N-terminal half of the Gla domain of vitamin K-dependent clotting proteins [146]. Mg
2+ enhances 
factor IXa binding to phospholipids at physiological concentrations of Ca
2+. This fact could facilitate 
assembly of the intrinsic tenase complex. It has been concluded that Mg
2+ promotes phospholipid 
binding to all vitamin K-dependent clotting proteins [147].  
7.3. Other Functions of Magnesium on Phospholipids 
Magnesium  is  necessary  in  eukaryotic  cells  for  phosphatidate  phosphatase  (PAP,  
3-sn-phosphatidate phosphohydrolase, EC 3.1.3.4) activity. This enzyme plays a central role in the 
synthesis of phospholipids and triacylglycerol through its product diacylglycerol, and it also generates 
and/or degrades lipid-signaling molecules that are related to phosphatidate. The requirement of Mg
2+ 
ions as a cofactor for PAP enzymes is correlated with the catalytic motifs that govern the phosphatase 
reactions of these enzymes. For example, the PAH1-encoded PAP1 enzyme has a DxDxT catalytic 
motif within a haloacid dehalogenase (HAD)-like domain [148]. This motif is found in a superfamily 
of Mg
2+-dependent phosphatase enzymes, and its first aspartate residue is responsible for binding the 
phosphate moiety in the phosphatase reaction [149]. 
Furthermore,  Mg  deficiency  increases  AA  in  renal  epithelial  NRK-52E  cells,  where  the 
extracellular Mg
2+ removal elevates AA release mediated mainly by Ca
2+-independent phospholipase A2 
(iPLA2) [150]. In addition, Mg influences the profile of fatty acids and their esters in rat hepatocytes. 
Hepatocytes incubated with MgCl2 in the culture medium showed a decrease of the amount of C18:2, 
C18:1b  and  C20:4  in  comparison  with  the  control  sample  [151].  The  experimental  evidence  also 
indicates that the n−6/n−3 fatty acid composition of the diet or the physiological factors affecting 
oxidative stress can alter the response of rats to marginal Mg deficiency by modifying Mg metabolism, 
distribution  and  oxidative  stress  indicators  [152].  All  these  observations  demonstrate  a  complex 
relationship between Mg homeostasis and phospholipid metabolism. 
8. Conclusion 
The experimental evidence presented in this review indicates that fatty acids, vitamins (A, E and 
folate)  and  essential  metals  (zinc  and  magnesium)  play  an  important  role  in  the  phospholipid Int. J. Mol. Sci. 2011, 12                     
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metabolism of different organs of animal or human cells. Cardiovascular and mental disease, several 
lung pathologies and cancer, among other human disorders, exhibit a phospholipid component in their 
epidemiology. For this reason, further understanding of the role played by macro and micronutrients in 
phospholipid homeostasis should contribute to the prevention and treatment of prevalent diseases in 
the world. However, further discussion and research on the interactions among dietary components, 
phospholipid metabolism, multiple genes, and risk factors is still required. 
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